Navigation Links
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Date:3/13/2008

aceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertaintie
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Exotic Automation & Supply ... launch of http://www.cng.exoticautomation.com , an ecommerce website ... way to purchase genuine OEM replacement CNG, LPG ... The new website provides owners of fleets ranging ... to high performance products for their vehicle maintenance ...
(Date:5/5/2015)... The Alliance for Clinical Research Excellence ... in the public interest, and Texas-based for-profit San ... Company, have formed a strategic alliance to create a ... across the healthcare and clinical research endeavor. The ... and the public to be clearly heard in this ...
(Date:5/4/2015)... May 4, 2015   St. Jude Children,s ... better computer tool for finding genetic alterations that ... were difficult to identify with whole-genome sequencing. The ... Nature Methods . The tool is ... Segmentation by Regression Tree in Next Generation Sequencing. ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - Fluorinov Pharma ... announce the appointment of Dr. Roger J Garceau, ... guiding biotech companies in matters including corporate development ... team and adds significant regulatory expertise as Fluorinov ... Garceau brings 30 years of pharmaceutical development experience ...
Breaking Biology Technology:Exotic Automation & Supply Launches Ecommerce Website 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 4Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... More Than Doubles Assets Under Management, UTRECHT, The ... European venture capital firm, today announced,the closing of its ... II (GHC II). The new fund, which is Gilde,s ... raised to invest in European,healthcare opportunities. GHC II was ...
... to grow forests of tiny cylinders called carbon nanotubes ... flow of heat at a critical point where the ... The carpetlike growth of nanotubes has been shown to ... nanotube layer does not require elaborate clean-room environments, representing ...
... 2 The Foundation for,Biomedical Research (FBR) congratulates ... DeBakey the highest civilian honor it can bestow, ... to cardiovascular medicine,have improved the health of millions ... extraordinary talents as a surgeon, inventor, educator and,medical ...
Cached Biology Technology:Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund 2Nanotube forests grown on silicon chips for future computers, electronics 2Nanotube forests grown on silicon chips for future computers, electronics 3Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal 2
(Date:4/27/2015)... April 27, 2015  For more than four decades, ... has been the premier worldwide event for the unmanned ... a must-attend event for any local, national, or trade ... emerging commercial markets and current applications of unmanned technologies. ... this projected $48 billion industry, and how it will ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... energy from walking, breathing, and other natural body movements ... pacemakers. In a study in ACS, monthly journal, ... rubber films for use in implantable or wearable energy ... to harvest energy from the motion of the lungs ...
... Current research suggests that nitric oxide may play a role ... by Mittal et al, "Inhibition of inducible nitric oxide controls ... Escherichia coli K1 in neonatal meningitis," appears in the ... . Bacterial meningitis, or inflammation of the membranes ...
... Not Affect MRSA-Induced Pneumonia A group led ... Molecular and Translational Human Infectious Diseases Research of The ... that the cytotoxin Paton-Valentine leukocidin (PVL) does not affect ... Their report can be found in the March ...
Cached Biology News:Treating neonatal meningitis -- is nitric oxide a foe or a friend to bacteria? 2Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5
... The Dyad Disciple thermal cycler is ... It may also be operated independently, using ... variety of interchangeable Alpha units (sample-holder, heat-pump ... well as the Chromo4 real-time detector. Peltier ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...
...
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
Biology Products: